Advertisement

Topics

Latest "Onxeo S.A." News Stories

21:13 EDT 17th October 2018 | BioPortfolio

Here are the most relevant search results for "Onxeo S.A." found in our extensive news archives from over 250 global news sources.

More Information about Onxeo S.A. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Onxeo S.A. for you to read. Along with our medical data and news we also list Onxeo S.A. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Onxeo S.A. Companies for you to search.

Showing "Onxeo" News Articles, all 20

Sunday 14th October 2018

Onxeo SA Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 28072018] Prices from USD $350

Onxeo SA Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Onxeo SA Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Onxeo SA since January20...


Monday 1st October 2018

Onxeo SA ONXEO Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13082018] Prices from USD $250

SummaryOnxeo SA Onxeo is a manufacturer of drugs that offers development, and registration of orphan oncology drugs for the treatment of cancer. The company provides pipeline products such as livatag, belchop, beleodaq, amep, asidna and validive, among others. It offers drugs for the treatment of liver cancer, and treatment and prevention of radio chemotherapy, head cancer and neck cancer, among o...

Thursday 13th September 2018

Onxeo to Attend Key Investor and Partnering Conferences in the Coming Months

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, today a...


Tuesday 14th August 2018

Onxeo SA Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 31052018] Prices from USD $350

Onxeo SA Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Onxeo SA Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Onxeo SA since January20...

Friday 3rd August 2018

Onxeo: Publication of the 2018 Half-Yearly Financial Report

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, in part...

Monday 30th July 2018

Onxeo SA ONXEO Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 09052018] Prices from USD $250

SummaryOnxeo SA Onxeo is a biopharmaceutical company that offers development, and registration of orphan oncology drugs for the treatment of cancer. The company's pipeline products include livatag, belchop, beleodaq, amep, asidna, validive, and others. It provides drugs for the treatment of liver cancer, and treatment and prevention of radio chemotherapy, head cancer and neck cancer. Onxeo's livat...

Friday 27th July 2018

Onxeo Reports Half-Year 2018 Financial Results and Provides Business Outlook

Clinical development of Onxeo’s lead product candidate AsiDNA™ progressing to plan Preliminary safety and activity results of DRIIV-1 study are expected in Q4 2018 Two combination clinical trials with AsiDNA™ planned for early 2019 Ne...

Thursday 12th July 2018

New Preclinical Results on Onxeo’s AsiDNA™, First-in-Class DNA Repair Inhibitor, Point to Strong Synergy and Reversion of Tumor Resistance when combined to PARP inhibitors

AsiDNA™ combined with olaparib* more than doubled the complete response rate observed with olaparib alone in an in vivo model of triple negative breast cancer resistant to PARP inhibitors AsiDNA™ combined with olaparib inhibited tumor growth in an in vivo model of ovarian cancer resistant to olaparib AsiDNA...

Wednesday 11th July 2018

New Preclinical Results on Onxeo’s AsiDNA™, First-in-Class DNA Repair Inhibitor, Point to ...

Read more...

Friday 6th July 2018

Summary of Onxeo's Liquidity Contract with CM-CIC Securities

Regulatory News: Pursuant to the liquidity contract granted to CM-CIC SECURITIES regarding Onxeo (Paris:ONXEO) (NASDAQ OMX:ONXEO) shares, the following resources were listed in the liquidity accou...

Thursday 21st June 2018

Deals and M&As this week: Alliance Pharma, Bayer, Onxeo

Alliance Pharma plans to acquire exclusive distribution rights to Nizoral, an anti-dandruff brand, from Janssen Pharmaceutica NV for £60m ($79.5m). Alliance...Read More... The post Deals and M&As this week: Alliance Pharma, Bayer, Onxeo appeared first on Pharmaceutical Technology.

Friday 15th June 2018

Onxeo Implements an Equity Line Financing Including an Incentive Program with Nice & Green SA

Cash for Operations Extended to Q3 2020 Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against rare or resistant cancers, today announces the initiation of an equity financin...

Wednesday 23rd May 2018

Onxeo to Present at BIO International Convention in Boston

PARIS–(BUSINESS WIRE)–Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, notably against rare or resistant forms of cancer, today announced that Judith Greciet, the Company’s Chief Executive … Continue reading → Cet article Onxeo to Present at BIO Int...

Thursday 10th May 2018

Onxeo SA ONXEO Financial and Strategic SWOT Analysis Review [Report Updated: 09032018] Prices from USD $300

SummaryOnxeo SA Onxeo is a biopharmaceutical company that offers development, and registration of orphan oncology drugs for the treatment of cancer. The company's pipeline products include livatag, belchop, beleodaq, amep, asidna, validive, and others. It provides drugs for the treatment of liver cancer, and treatment and prevention of radio chemotherapy, head cancer and neck cancer. Onxeo's livat...

Friday 27th April 2018

Onxeo (ONXEO) - Phase I with AsiDNA iv starts; first data in H218

Edison Investment Research - Pharmaceutical & healthcare - Onxeo: On 24 April, Onxeo announced that the first patient had been treated with AsiDNA, a first-in-class DNA break repair inhibitor, via systemic administration in the Phase I trial. AsiDNA has already generated supportive data from a Phase I trial in melanoma using intratumoural injection. Alongside the Phase I trial Onxeo is conducting ...

Wednesday 25th April 2018

Onxeo S.A.: Publication of 2017 Registration Document

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against ...

Onxeo S.A.: Combined General Meeting on May 16, 2018

Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a biotechnology company specializing in the development of innovative drugs in oncology, in particular against ...

Cancer Treatment Targeting DNA Repair is Tested in Humans for the First Time

Onxeo has initiated a Phase I trial testing its first-in-class cancer treatment that works by inhibiting the repair of tumor DNA. Onxeo, a French biotech, has dosed its first patient in a Phase I study testing its cancer treatment AsiDNA, ... This awesome article Cancer Treatment Targeting DNA Repair is Tested in Humans for the First Time appeared first on Labiotech.eu. Be kind and don't copy it w...

Tuesday 3rd April 2018

Onxeo SA Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 18022018] Prices from USD $350

Onxeo SA Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Onxeo SA Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Onxeo SA since January20...

Thursday 29th March 2018

Onxeo Reports Full-Year 2017 Financial Results and Provides Business Update

Advancement of core pipeline assets on track with key development catalysts expected in 2018 First new molecule generated from platON, Onxeo's proprietary development platform, to enter preclinica...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks